The purpose of this study is to find out what might increase nerve damage in people with HIV who have taken drugs for treatment of HIV disease. Another purpose is to see if nerve exams are done correctly before clinical research sites enroll HIV-infected patients. Nerve damage is common in patients with HIV infection and can cause serious problems. The factors that place patients at risk are not well understood. This study will examine these factors in patients with advanced HIV infection and who have been taking anti-HIV drugs.

Condition
HIV Infections Peripheral Nervous System Disease

Further Study Details: 

Expected Total Enrollment:  100

Neurological complications in HIV infection are common and are significant sources of mortality and morbidity. The associated risk factors have not been clearly defined. Several studies have patients who are suited for analysis of peripheral neuropathy and can address the important clinical question of when a subject with asymptomatic neuropathy is most at risk for progressing to painful neuropathy. Some patients in this population with advanced HIV disease will likely have asymptomatic peripheral neuropathy at baseline, and will present an excellent opportunity for prospective study. Detailed quantitative assessments will be carried out to determine the incidence and course of peripheral neuropathy in this population. Risk factors for the development of new peripheral neuropathy, worsening of existing neuropathy, and progression to symptomatic peripheral neuropathy, such as CD4+ cell counts, HIV-1 viral load, and prior nucleoside analogue use, will be evaluated. The potential additive neurotoxic effects of hydroxyurea exposure in this population can also be analyzed.

HIV-infected patients are characterized for the presence or absence of neuropathy at [AS PER AMENDMENT 03/05/02: screening], baseline, Week 24, and Week 48. Entry variables are analyzed to determine predictors of progression from asymptomatic to symptomatic neuropathy or for worsening of symptomatic neuropathy. HIV-uninfected control volunteers have 1 visit [AS PER AMENDMENT 03/05/02: or 2 visits] for nerve conduction and Quantitative Sensory Testing (QST) evaluations to demonstrate proficiency with the testing methods prior to the enrollment of HIV-infected patients. HIV-infected patients are evaluated with the components of the Total Neuropathy Score (TNS) which includes signs (motor function, sensory function, and reflexes), symptoms (motor symptoms and sensory symptoms), QST (CASE IV - vibratory, cooling, and heat pain thresholds), and nerve conduction studies (sural nerve and peroneal nerve). Other evaluations include the Gracely Pain Scale and Visual Analog Scale pain diaries, paired skin biopsies from the right thigh and distal leg (total of 2), and peripheral blood lymphocyte analysis for quantitation of mitochondrial DNA content at entry and final study visit.

Ages Eligible for Study:  13 Years and above,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

Inclusion Criteria

Control volunteers will be eligible for this study if they:

• Are HIV negative.
• Are at least 18 years old.

Patients will be eligible for this study if they:

• Are HIV positive.
• Are at least 13 years old and can provide written consent from parent or guardian if under 18 years of age.
• Have taken anti-HIV drugs for at least 15 straight weeks any time in the past.
• Have a CD4 count of less than 300 cells/mm3.

Exclusion Criteria

Control volunteers will not be eligible for this study if they:

• Have any nerve-related problems.
• Have diabetes and nerve damage related to diabetes.
• Have long-term illness the doctor feels would interfere with the study.

Patients will not be eligible for this study if they:

• Have had spinal surgery.
• Have taken insulin or oral hypoglycemic products for diabetes mellitus within 30 days prior to study entry. Dietary control for diabetes is allowed.
• Have nerve damage related to diabetes.
• Have a nerve condition unrelated to HIV infection or antiretroviral therapy.
• Have alcohol-related medical complications within 6 months of study entry.
• Have vitamin B12 levels of less than 200 pg/ml or a history of vitamin B12 deficiency.

This study has been changed to modify the exclusion criteria. Earlier versions did not include some of these exclusion criteria.

Alabama
      Univ of Alabama at Birmingham, Birmingham,  Alabama,  35294,  United States
California
      UCLA CARE Ctr, Los Angeles,  California,  90095,  United States
Colorado
      Univ of Colorado Health Sciences Ctr, Denver,  Colorado,  80262,  United States
Hawaii
      Univ of Hawaii, Honolulu,  Hawaii,  96816,  United States
Illinois
      The CORE Ctr, Chicago,  Illinois,  60612,  United States
Indiana
      Indiana Univ Hosp, Indianapolis,  Indiana,  462025250,  United States
      Methodist Hosp of Indiana / Life Care Clinic, Indianapolis,  Indiana,  46202,  United States
      Wishard Hosp, Indianapolis,  Indiana,  46202,  United States
Maryland
      Johns Hopkins Hosp, Baltimore,  Maryland,  21287,  United States
Missouri
      Washington Univ School of Medicine, St. Louis,  Missouri,  63108,  United States
      Washington Univ / St Louis Connect Care, Saint Louis,  Missouri,  63108,  United States
New York
      Univ of Rochester Medical Center, Rochester,  New York,  14642,  United States
      Cornell Univ Med Ctr, New York,  New York,  10021,  United States
      Beth Israel Med Ctr, New York,  New York,  10003,  United States
Pennsylvania
      Univ of Pennsylvania, Philadelphia,  Pennsylvania,  19104,  United States
      Mount Sinai Med Ctr, Pittsburgh,  Pennsylvania,  15213,  United States
Texas
      Univ of Texas, Southwestern Med Ctr of Dallas, Dallas,  Texas,  75390,  United States
Washington
      Univ of Washington, Seattle,  Washington,  98104,  United States

Study chairs or principal investigators

David Simpson,  Study Chair

Study ID Numbers:  ACTG A5117; AACTG A5117
Record last reviewed:  August 2004
Last Updated:  October 13, 2004
Record first received:  June 11, 2001
ClinicalTrials.gov Identifier:  NCT00017771
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08